期刊文献+

奥氮平与阿立哌唑治疗精神分裂症的疗效对比分析 被引量:7

The Comparative Study on Efficacy of Olanzapine and Aripiprazole in Treatment of Schizophrenia
在线阅读 下载PDF
导出
摘要 目的:对奥氮平与阿立哌唑治疗精神分裂症的疗效进行对比分析。方法选取我院于2013年9月~2014年10月收治的40例精神分裂症患者随机分成对照组和治疗组,分别采用阿立哌唑和奥氮平治疗,对所有患者进行为期8周的治疗,观察两组的治疗效果以及不良反应发生情况。结果对照组和治疗组的治疗总有效率分别为80%和95%,不良反应发生率分别为25%和10%,两组结果对比差异显著,有统计学意义(P<0.05)。结论采用奥氮平治疗精神分裂症的治疗疗效显著优于阿立哌唑,并且不良发应情况较少,对治疗精神分裂症有着重要的临床应用价值。 Objective The ef icacy of Olanzapine and Aripiprazole in treatment of schizophrenia is to be comparatively analyzed.Methods Choose 40 schizophrenia patients who are treated in hospital from September 2013 to October 2014 and separate them into control group and study group at random, treat these patients of two groups with Aripiprazole and Olanzapine treatment respectively as long as 8 weeks;and then observe the treatment ef icacy as wel as side-ef ect probability of these two groups. Results The treatment ef iciency of control group and study group are 80%and 95%respectively, while the side-ef ect incidence of control group and study group are 25%and 10%respectively;there is a treatment dif erential between the two groups, and such a dif erential has statistic value(P〈0.05). Conclusion Olanzapine is much more ef ective and favorable than Aripiprazole in treatment of schizophrenia patients;besides, Olanzapine treatment has fewer side ef ects compared to Aripiprazole, therefore, Olanzapine treatment is quite worthwhile to be promoted and applied in treatment of schizophrenia.
作者 王新玉
出处 《中国卫生标准管理》 2015年第1期170-171,共2页 China Health Standard Management
关键词 奥氮平 阿立哌唑 精神分裂症 疗效 Olanzapine Aripiprazole Schizophrenia Efficacy
  • 相关文献

参考文献3

二级参考文献21

  • 1梁峻铭,陈大坤.阿立哌唑与氟哌啶醇治疗精神分裂症对照研究[J].中国药业,2005,14(6):82-82. 被引量:14
  • 2符传创,刘学兵,卢佩贤,郑庆梅,杨光.阿立哌唑治疗首发精神分裂症30例临床观察[J].海南医学,2005,16(6):112-112. 被引量:21
  • 3马兆峰,陈希,庄晓华,张立亮.奥氮平对精神分裂症患者疗效及生活质量的影响[J].中国行为医学科学,2005,14(8):723-724. 被引量:8
  • 4敖翔,许海云,宋红梅,李祥,潘勇,邵群.阿立哌唑对女性精神分裂症患者生活质量的影响[J].中国民康医学,2006,18(23):1005-1006. 被引量:5
  • 5Deleon A, Patel NC, Crismon ML. Aripiprazole : a comprehensive review of its pharmacology, clinical efficacy, and tolerability [ J ]. C lin Ther,2004 ,26 :649 - 666.
  • 6Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazale is a potent,partial agonist at the human 5 - HT1A receptoc[ J]. Eur J Pharmacol,2002,441 : 137 - 140.
  • 7Yokoi F, Grunder G, Biziere K, et al. Dopamine D2and D3 receptor occupancy in normal humans treated with the antipsyehotic drug aripiprazole (0PG14597): a study using positron emission tomography and raclopride[ J]. Neuropsycharmacology,2002,27 : 248 - 258.
  • 8Newcomer JM. Metabolic risk during antipsychotic treatment [ J ]. Clin Ther,2004,26 : 1936 - 1956.
  • 9Bryan LR, Douglas S, Potkin SG. Atypical antipsychotic drug actions : unitary or multiple mechanisms for atypicality7 [J]. Clin Neurosci Res,2003,3 : 108 - 117.
  • 10中华医学会精神科分会.中国精神障碍分类与诊断标准[M]济南:山东科学技术出版社,200175-88.

共引文献40

同被引文献45

引证文献7

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部